Van Mieghem Eugénie, Intan-Goey Valent, Buffet Wendi, Lammens Martin, Van Loo Pieter, Abrams Pascale
Department of Internal Medicine, GZA Hospitals, Antwerpen, Belgium.
Department of Pathological Anatomy, GZA Hospitals, Antwerpen, Belgium.
Endocrinol Diabetes Metab Case Rep. 2022 Mar 1;2022. doi: 10.1530/EDM-21-0168.
Pituitary carcinoma is a rare type of malignancy and only accounts for 0.1-0.2% of all pituitary tumours. Most pituitary carcinomas are hormonally active and they are mostly represented by corticotroph and lactotroph carcinomas. Corticotroph carcinoma can present as symptomatic Cushing's disease or can evolve from silent corticotroph adenoma which is not associated with clinical or biochemical evidence of hypercortisolism. We hereby present a case of a bone-metastasized corticotroph pituitary carcinoma masquerading as an ectopic adrenocorticotropic hormone (ACTH) syndrome in a patient with a history of a non-functioning pituitary macro-adenoma. Our patient underwent two transsphenoidal resections of the primary pituitary tumour followed by external beam radiation therapy. Under hydrocortisone substitution therapy she developed ACTH-dependent hypercortisolism without arguments for recurrence on pituitary MRI and without central-to-peripheral ACTH-gradient on inferior petrosal sinus sampling, both suggesting ectopic production. Ultimately, she was diagnosed with an ACTH-secreting vertebral metastasis originating from the primary pituitary tumour. This case report demonstrates the complex pathophysiology of pituitary carcinoma and the long diagnostic work-up. Certain features in pituitary adenoma should raise the suspicion of malignancy.
The diagnosis of pituitary carcinoma can only be made based on documented metastasis, therefore, due to the often long latency period between the detection of the primary tumour and the occurrence of metastasis, the diagnostic work-up most often spans over multiple years. Pituitary carcinoma including corticotroph carcinoma is very rare in contrast to pituitary adenoma and only accounts for 0.1-0.2% of all pituitary tumours. Histopathology in pituitary adenoma should certainly accomplish the following goals: accurate tumour subtyping and assessment of tumoural proliferative potential. Repeated recurrence of pituitary adenoma after surgical resection, a discrepancy between biochemical and radiological findings, resistance to medical and radiation therapy, and silent tumours becoming functional are all hallmarks of pituitary carcinoma. Silent corticotroph adenomas are non-functioning pituitary adenomas that arise from T-PIT lineage adenohypophyseal cells and that can express adrenocorticotropic hormone on immunohistochemistry, but are not associated with biochemical or clinical evidence of hypercortisolism. Silent corticotroph adenomas exhibit a more aggressive clinical behaviour than other non-functioning adenomas. Treatment options for corticotroph carcinoma include primary tumour resection, radiation therapy, medical therapy, and chemotherapy. Sometimes bilateral adrenalectomy is necessary to achieve sufficient control of the cortisol excess.
垂体癌是一种罕见的恶性肿瘤,仅占所有垂体肿瘤的0.1 - 0.2%。大多数垂体癌具有激素活性,主要表现为促肾上腺皮质激素细胞癌和催乳素细胞癌。促肾上腺皮质激素细胞癌可表现为有症状的库欣病,也可由无皮质醇增多症临床或生化证据的静止性促肾上腺皮质激素细胞腺瘤演变而来。我们在此报告一例骨转移的促肾上腺皮质激素细胞垂体癌病例,该患者有非功能性垂体大腺瘤病史,临床表现为异位促肾上腺皮质激素(ACTH)综合征。我们的患者接受了两次经蝶窦原发性垂体肿瘤切除术,随后进行了外照射放疗。在氢化可的松替代治疗期间,她出现了ACTH依赖性皮质醇增多症,垂体MRI未显示复发迹象,岩下窦取样未发现中央至外周ACTH梯度,这两者均提示异位分泌。最终,她被诊断为源自原发性垂体肿瘤的ACTH分泌性椎体转移瘤。本病例报告展示了垂体癌复杂的病理生理学和漫长的诊断过程。垂体腺瘤的某些特征应引起对恶性肿瘤的怀疑。
垂体癌的诊断只能基于有记录的转移,因此,由于原发性肿瘤检测与转移发生之间通常存在较长的潜伏期,诊断过程往往持续数年。与垂体腺瘤相比,包括促肾上腺皮质激素细胞癌在内的垂体癌非常罕见,仅占所有垂体肿瘤的0.1 - 0.2%。垂体腺瘤的组织病理学当然应实现以下目标:准确的肿瘤亚型分类和肿瘤增殖潜能评估。垂体腺瘤手术切除后反复复发、生化和影像学检查结果不一致、对药物和放疗耐药以及静止性肿瘤出现功能异常都是垂体癌的特征。静止性促肾上腺皮质激素细胞腺瘤是起源于T-PIT谱系腺垂体细胞的无功能性垂体腺瘤,免疫组化可表达促肾上腺皮质激素,但无皮质醇增多症的生化或临床证据。静止性促肾上腺皮质激素细胞腺瘤比其他无功能性腺瘤表现出更具侵袭性的临床行为。促肾上腺皮质激素细胞癌的治疗选择包括原发性肿瘤切除、放疗、药物治疗和化疗。有时需要双侧肾上腺切除术以充分控制皮质醇过量。